All existing shareholders contributed to the Marine Biological Laboratory spinout’s series B round, following a $91.5m series A in mid-2020.

Korro Bio, a US-based RNA editing technology developer based on research at University of Chicago-affiliated Marine Biological Laboratory, secured $116m in series B financing led by Eventide Asset Management last week.

Fidelity Management & Research, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital and an unnamed healthcare specialist fund invested in the company alongside all existing backers.

Existing shareholders include Atlas Venture, New Enterprise Associates (NEA), Wu Capital, Qiming Venture Partners USA, Surveyor Capital, Cormorant Asset Management,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email Linked in